N/A N=72 The Efficacy of Thoracoabdominal Nerve Block With Serratus Intercostal Plane and Rectus Sheath Block in Cholecystectomy
Pain Management
Primary: Postoperative Pain Examination — 3; 5; 2; 3 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=206 A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Clinical Trial of Reproxalap to Assess the Safety and Efficacy in Subjects With Dry Eye Disease
Dry Eye
Primary: Change From Baseline in Subject-reported Ocular Dryness Score (0 - 100 Visual Analogue Scale (VAS)) — -16.0; -9.1 score on a scale
Phase 2 N=38 NAP in Combination With Docetaxel Following Obinutuzumab Pretreatment in Subjects With Checkpoint Inhibitor Pretreated Advanced or Metastatic NSCLC
Non-small Cell Lung Cancer
Primary: Objective Response Rate (ORR) — 15.6 percentage of responders
Phase 2 N=115 Lipoic Acid for Progressive Multiple Sclerosis (MS)
Multiple Sclerosis
Primary: Change in Mobility: Timed 25 Foot Walk — -0.39; -0.30 feet per second — p=0.51
Phase 1 N=9 Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid Tumors
Advanced Solid Tumor
Primary: Determine Disease Response Following 2 or 3 CPX-POM Treatment Cycles by Assessing the Complete and Partial Pathologic Response Rate at the Time of Radical Cystectomy…
N/A N=54 Better Together Study
Type 2 Diabetes
Primary: Recruitment Group Preference — 54 participants
N/A N=49 Establishing the Effectiveness of Publicly Available Smoking Cessation Resource
Smoking Cessation
Primary: Self-reported Smoking Cessation — 16 Participants
N/A N=141 Clinical Trial of H2-BP Electronic Sphygmomanometer
Low Blood Pressure · Normal Blood Pressure · Prehypertension
Primary: Mean and Standard Deviation of Differences Between H2-BP Device and Aneroid Sphygmomanometer Measurements. — 0,276; -0,004 kPa
Phase 4 N=26 The Role of Acute Combined PPAR Alpha and Gamma Stimulation on Insulin Action in Humans
Type 2 Diabetes Mellitus
Primary: Endogenous Glucose Production (EGP) — 1.26; 1.25; 0.90; 1.48 mg/kg/min
Phase 4 N=60 Liraglutide and Peripheral Artery Disease
Type 2 Diabetes · Peripheral Arterial Disease
Primary: Peripheral Transcutaneous Oxygen Pressure — 54.2; 43.4 mmHg — p=<0.001
N/A N=58 Social-LEAF Life Enhancing Activities for Caregivers
Social Connectedness
Primary: Patient Reported Outcome Measurement Information System (PROMIS )Positive Affect — -1.7; -0.3 units on a scale — p=0.57
N/A N=109 Pre-epidural Sequential Compression Devices (SCDs) to Prevent Hypotension During Labor
Hypotension · Labor Complication
Primary: Hypotension — 4; 4 participants
N/A N=1,238,835 Improving BP Control in Diverse Populations Using BP MAP
Hypertension
Primary: Change in Blood Pressure Control, % of Patients — 2.8; 1.6; -0.4 percentage of patients
Phase 4 N=66 The Effect of Lipid Emulsions on Free Fatty Acids and Free Bilirubin in Premature Newborns
Prematurity
Primary: Free Bilirubin (UB) Serum Levels — 10.5; 9.4 Nanomoles/Liter (nM)
Phase 2 N=280 A Phase 2b Study of Icosabutate in Fatty Liver Disease
Non Alcoholic Steatohepatitis (NASH)
Primary: Percentage of Patients With Resolution of NASH, Defined as Disappearance of Ballooning (Score = 0) With Lobular Inflammation Score 0 or 1, With no Worsening of Fibrosis…